{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:09:20Z","timestamp":1780582160289,"version":"3.54.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>West Nile virus (WNV) is the leading cause of arboviral disease in the United States and is associated with significant morbidity and mortality. A previous analysis found that a vaccination program targeting persons aged \u226560 years was more cost-effective than universal vaccination, but costs remained high.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used a mathematical Markov model to evaluate cost-effectiveness of an age- and incidence-based WNV vaccination program. We grouped states and large counties (\u2265100 000 persons aged \u226560 years) by median annual WNV incidence rates from 2004 to 2017 for persons aged \u226560 years. We defined WNV incidence thresholds, in increments of 0.5 cases per 100 000 persons \u226560 years. We calculated potential cost per WNV vaccine-prevented case and per quality adjusted life-years (QALYs) saved.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Vaccinating persons aged \u226560 years in states with an annual incidence of WNV neuroinvasive disease of \u22650.5 per 100 000 resulted in approximately half the cost per health outcome averted compared to vaccinating persons aged \u226560 years in the contiguous United States. This approach could potentially prevent 37% of all neuroinvasive disease cases and 63% of WNV-related deaths nationally. Employing such a threshold at a county level further improved cost-effectiveness ratios while preventing 19% and 30% of WNV-related neuroinvasive disease cases and deaths, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>An age- and incidence-based WNV vaccination program could be a more cost-effective strategy than an age-based program while still having a substantial impact on lowering WNV-related morbidity and mortality.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciab540","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T19:21:37Z","timestamp":1623266497000},"page":"1565-1570","source":"Crossref","is-referenced-by-count":16,"title":["Cost-Effectiveness and Impact of a Targeted Age- and Incidence-based West Nile Virus Vaccine Strategy"],"prefix":"10.1093","volume":"73","author":[{"given":"Emily J","family":"Curren","sequence":"first","affiliation":[{"name":"Division of Vector-Borne Diseases, Centers for Disease Control and Prevention (CDC), Fort Collins, Colorado, USA"},{"name":"Epidemic Intelligence Service, CDC, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath B","family":"Shankar","sequence":"additional","affiliation":[{"name":"First Principles Inc., Bangalore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Fischer","sequence":"additional","affiliation":[{"name":"Division of Vector-Borne Diseases, Centers for Disease Control and Prevention (CDC), Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin I","family":"Meltzer","sequence":"additional","affiliation":[{"name":"Division of Preparedness and Emerging Infections, CDC, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Erin Staples","sequence":"additional","affiliation":[{"name":"Division of Vector-Borne Diseases, Centers for Disease Control and Prevention (CDC), Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn V","family":"Gould","sequence":"additional","affiliation":[{"name":"Division of Vector-Borne Diseases, Centers for Disease Control and Prevention (CDC), Fort Collins, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,12]]},"reference":[{"key":"2021110300071268400_CIT0001","doi-asserted-by":"crossref","first-page":"673","DOI":"10.15585\/mmwr.mm6831a1","article-title":"West Nile virus and other domestic nationally notifiable arboviral diseases\u2014United States, 2018","volume":"68","author":"McDonald","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021110300071268400_CIT0002","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1001\/jama.2013.8042","article-title":"West Nile virus: review of the literature","volume":"310","author":"Petersen","year":"2013","journal-title":"JAMA"},{"key":"2021110300071268400_CIT0003","author":"Centers for Disease Control and Prevention"},{"key":"2021110300071268400_CIT0004","first-page":"1","article-title":"Surveillance for human West Nile virus disease\u2014United States, 1999\u20132008","volume":"59","author":"Lindsey","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021110300071268400_CIT0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0140-6736(01)05480-0","article-title":"Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey","volume":"358","author":"Mostashari","year":"2001","journal-title":"Lancet"},{"key":"2021110300071268400_CIT0006","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/rmv.501","article-title":"Manifestations of West Nile neuroinvasive disease","volume":"16","author":"Sejvar","year":"2006","journal-title":"Rev Med Virol"},{"key":"2021110300071268400_CIT0007","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1086\/518281","article-title":"The long-term outcomes of human West Nile virus infection","volume":"44","author":"Sejvar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2021110300071268400_CIT0008","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4269\/ajtmh.2012.12-0113","article-title":"Medical risk factors for severe West Nile virus disease, United States, 2008\u20132010","volume":"87","author":"Lindsey","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"2021110300071268400_CIT0009","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4269\/ajtmh.13-0206","article-title":"Initial and long-term costs of patients hospitalized with West Nile virus disease","volume":"90","author":"Staples","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"2021110300071268400_CIT0010","article-title":"West Nile virus-associated hospitalizations, California, USA, 2004\u20132017","volume":"ciaa749","author":"Snyder","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021110300071268400_CIT0011","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3390\/v11090823","article-title":"Twenty years of progress toward West Nile virus vaccine development","volume":"11","author":"Kaiser","year":"2019","journal-title":"Viruses"},{"key":"2021110300071268400_CIT0012","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/infdis\/jiq003","article-title":"Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults","volume":"203","author":"Biedenbender","year":"2011","journal-title":"J Infect Dis"},{"key":"2021110300071268400_CIT0013","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1016\/j.vaccine.2012.08.063","article-title":"Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults \u2265 50 years of age","volume":"30","author":"Dayan","year":"2012","journal-title":"Vaccine"},{"key":"2021110300071268400_CIT0014","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1016\/j.vaccine.2013.07.064","article-title":"The live attenuated chimeric vaccine rWN\/DEN4\u039430 is well-tolerated and immunogenic in healthy flavivirus-naive adult volunteers","volume":"31","author":"Durbin","year":"2013","journal-title":"Vaccine"},{"key":"2021110300071268400_CIT0015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3201\/eid1203.050782","article-title":"Cost-effectiveness of West Nile virus vaccination","volume":"12","author":"Zohrabian","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"2021110300071268400_CIT0016","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1016\/j.vaccine.2016.11.078","article-title":"Cost effectiveness of a targeted age-based West Nile virus vaccination program","volume":"35","author":"Shankar","year":"2017","journal-title":"Vaccine"},{"key":"2021110300071268400_CIT0017","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3201\/eid1603.090667","article-title":"Economic cost analysis of West Nile virus outbreak, Sacramento County, California, USA, 2005","volume":"16","author":"Barber","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"2021110300071268400_CIT0018","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1086\/656602","article-title":"West Nile fever characteristics among viremic persons identified through blood donor screening","volume":"202","author":"Zou","year":"2010","journal-title":"J Infect Dis"},{"key":"2021110300071268400_CIT0019","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0950268812001070","article-title":"Estimated cumulative incidence of West Nile virus infection in US adults, 1999\u20132010","volume":"141","author":"Petersen","year":"2013","journal-title":"Epidemiol Infect"},{"key":"2021110300071268400_CIT0020","volume-title":"Prevention effectiveness: a guide to decision analysis and economic evaluation","author":"Haddix","year":"2003"},{"key":"2021110300071268400_CIT0021","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/01.inf.0000091295.53969.6a","article-title":"Regional variation in the cost effectiveness of childhood hepatitis A immunization","volume":"22","author":"Jacobs","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"2021110300071268400_CIT0022","first-page":"1","article-title":"Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"55","author":"Advisory Committee on Immunization Practices","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"2021110300071268400_CIT0023","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.vaccine.2018.11.056","article-title":"Cost-effectiveness of adult vaccinations: a systematic review","volume":"37","author":"Leidner","year":"2019","journal-title":"Vaccine"},{"key":"2021110300071268400_CIT0024","author":"Advisory Committee on Immunization Practices (ACIP)"},{"key":"2021110300071268400_CIT0025","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/M18-2347","article-title":"A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations","volume":"170","author":"Prosser","year":"2019","journal-title":"Ann Intern Med"},{"key":"2021110300071268400_CIT0026","doi-asserted-by":"crossref","first-page":"895","DOI":"10.4269\/ajtmh.2012.11-0502","article-title":"Modifiable risk factors for West Nile virus infection during an outbreak\u2014Arizona, 2010","volume":"86","author":"Gibney","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"2021110300071268400_CIT0027","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1749-6632.2001.tb02706.x","article-title":"West Nile virus serosurvey and assessment of personal prevention efforts in an area with intense epizootic activity: Connecticut, 2000","volume":"951","author":"McCarthy","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"2021110300071268400_CIT0028","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJMp1210537","article-title":"Unpredictable and difficult to control\u2014the adolescence of West Nile virus","volume":"367","author":"Petersen","year":"2012","journal-title":"N Engl J Med"},{"key":"2021110300071268400_CIT0029","author":"Centers for Disease Control and Prevention"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab540\/39785842\/ciab540.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/9\/1565\/41060945\/ciab540.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/9\/1565\/41060945\/ciab540.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:09:17Z","timestamp":1635898157000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/9\/1565\/6297173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,12]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,6,12]]},"published-print":{"date-parts":[[2021,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab540","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,6,12]]}}}